Search
Von Willebrand factor human
go.drugbank.com/drugs/DB13133ApprovedInvestigationalThe human vWF is used to manage and control bleeding episodes in patients with von Willebrand disease and hemophilia A. It was first approved by the FDA in 2015. … [L40049] As vWF is normally present in the blood as a stable complex with coagulation factor III, therapeutic vWF products are also available as a combination product with [antihemophilic factor human]
Mixtures: BIOSTATE FOR INJECTION 50 iu/ml, FANHDI 250 U.I.Categories: von Willebrand factor and coagulation factor VIII in combinationNelarabine
go.drugbank.com/drugs/DB01280ApprovedInvestigational[A15220] Subsequently, nelarabine was also approved by both Health Canada and European Medicines Agency in 2007 under the trademark name ATRIANCE.[L45874,L45879] … [A258719] Nelarabine was first granted accelerated approval by the FDA on October 28, 2005, and was manufactured under the trademark name ARRANON by GlaxoSmithKline.
Products: NELARAMAX 250 MG/50 ML IV İNFÜZYONLUK ÇÖZELTİ , 6 ADET, NELARAMAX 250 MG/50 ML IV İNFÜZYONLUK ÇÖZELTİ , 1 ADETBuprenorphine
go.drugbank.com/drugs/DB00921ApprovedIllicitInvestigationalVet approved[A186263,A186266,A186269] Buprenorphine acts as a partial mu-opioid receptor agonist with a high affinity for the receptor, but lower intrinsic activity compared to other full mu-opioid agonists such … This effect can be beneficial, however, as dose-related side effects such as respiratory depression, sedation, and intoxication also plateau at around 32mg, resulting in a lower risk of overdose compared
Synonyms: 2-(N-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6α-yl)-3,3-dimethyl-2-butanolMixtures: Suboxone 8 mg/2 mg sublingual tablets, Suboxone 2 mg/0.5 mg sublingual tabletsPalonosetron
go.drugbank.com/drugs/DB00377ApprovedInvestigationalAs of 2008, it is the most recent 5-HT3 antagonist to enter clinical use. … It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of
Products: PALSET (Palonosetron Hydrochloride Solution for Injection 0.05 mg/ml, 5 ml vial), PALOCIP® 250 MCG/5 MLAcylcarnitine (4Z,7Z,10E,12E,16Z)-18-(3-ethylcycloprop-1-en-1-yl)-14-hydroxyoctadeca-4,7,10,12,16-pentaenoylcarnitine
smpdb.ca/view/SMP0123577Metabolic-1-en-1-yl)-14-hydroxyoctadeca-4,7,10,12,16-pentaenoylcarnitine. … inner membrane to once again form (4Z,7Z,10E,12E,16Z)-18-(3-ethylcycloprop-1-en-1-yl)-14-hydroxyoctadeca-4,7,10,12,16-pentaenoyl-CoA and L-carnitine. (4Z,7Z,10E,12E,16Z)-18-(3-ethylcycloprop-1-en-1-yl
Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 moreInsulin degludec
go.drugbank.com/drugs/DB09564ApprovedInvestigational[A18561,A18562,A18563,A18564,A174934] Compared to available long-acting analogs such as [DB00047] and [DB01307], which have a duration of action of 20-24 hours, insulin degludec provides a consistent level … to endogenous insulin, and in the long term, damage to pancreatic islet cells.
Mixtures: Xultophy Pre-filled Pen, RYZODEG 100 UNIDADES/MLCategories: Drugs Used in DiabetesSacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigational[A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372,L47601] … [A193653] Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment.
Products: TRODELVY 200 MG İNFÜZYONLUK ÇÖZELTİ KONSANTRESİ İÇİN TOZ, 1 ADETPoractant alfa
go.drugbank.com/drugs/DB09113ApprovedInvestigationalIt is used to treat Respiratory Distress Syndrome (RDS) in premature infants with an endogenous pulmonary surfactant deficiency. … Poractant alfa is a pulmonary surfactant marketed as Curosurf in the United States and Canada.
Categories: Complex MixturesProducts: CUROSURF 240 MG/3 ML INTRATRAKEAL SUSPANSIYON IÇEREN FLAKON, 1 ADET, Curosurf 240 mg - Suspension zur endotracheopulmonalen InstillationBortezomib
go.drugbank.com/drugs/DB00188ApprovedInvestigational[A204083] In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. … [L14180] However, multiple mechanisms may be involved in the anticancer activity of bortezomib.[A204083] Bortezomib was first synthesized in 1995.
Synonyms: N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamideProducts: BORTEZOMIB EG, BORTEZOMIB SUNLumiracoxib
go.drugbank.com/drugs/DB01283ApprovedWithdrawnOn August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver … New Zealand and Canada have also followed suit in recalling the drug.
Products: PREXIGE ® 200 MG COMPRIMIDOS, PREXIGE ®100 MG COMPRIMIDOS